HIFP — Investment Memo

To: Series A prospective investors — health/longevity-strategic lead lane + AI-forward generalist warm-lane parallel From: Brandon Stauber (CPO/CTO) on behalf of the HIFP founder trio (Dr. Sindhu Pandit MD MBA · Dr. Fatima Paruk MD · Brandon Stauber) Date: 2026-09-14 (v4-draft-02 — supersedes draft-01 of 2026-09-09) Companion: HIFP-POV-v4 (strategic canonical) · HIFP-investor-deck-v4 (14-slide walk — draft) · HIFP-gtm-tier-strategy-v0.4 (four-lane GTM analytical spine) · HIFP-build-engineering-plan-v4 (16-week MVP + Series-A ladder; supersedes v0.1 timeline-compression cut-sheet + hustle plan) · HIFP-general-counsel-briefing-v0.1 (regulatory + IP posture) · HIFP-decision-log-2026-09-11 + HIFP-open-questions-2026-09-11 (post-check-in state). Distribution: NDA-only pending Karen general-counsel briefing (Ledger §3.24 · in flight — Sindhu texted 2026-09-11 to schedule coffee). 4-lane GTM tier structure RATIFIED at Friday 2026-09-11 check-in (Sindhu on record: "I am fine with those four areas").

Draft status. This is draft-02 pending two formal trio ratifications: (1) SAFE sizing at $2.5M target / $2.0M floor / $15M cap post-money — directionally adopted, silence-is-assent through Monday 2026-09-14 5pm PT per HIFP-decision-log-2026-09-11 §1; (2) exact Oracle title + preferred bio phrasing from Fatima — P0 blocker on §3 team bios; single-Slack-message-to-close. Both surface in §9.

Ask. SAFE seed round: $2.5M target · $2.0M floor · $15M cap post-money (directionally adopted 2026-09-11; $500K bump from prior $2.0M/$1.5M funds the 3rd founding engineer + HIPAA infrastructure baseline from Day 1 + Epic sandbox access + advisor-board budget — see §1.3 rationale). Structured to pivot to Series A within 6–9 months of close. Series A target Q1–Q2 2027 at $7–9M raise, led by health/longevity-strategic investor. Living-standard floor: $250K/founder/year + health insurance built into SAFE. Use of proceeds detailed §1.3 + §6.

Executive summary

HIFP is a category-defining opportunity to own the biomarker-informed planning decision at the point of trust — the concierge physician and the direct consumer — before wearable-longevity IPOs (Aura/Oura Sept 2026) and biomarker-lab consumer scale (Function 350K members, Superpower $199 founding tier) collide into an intersection no incumbent currently occupies.

Three reasons to write the check:

1. The category has no incumbent worth naming today, but has a 12–24-month window before one emerges. Genivity/Lumiant, the v1 competitive framing, is distressed at 7 employees mid-2026. Financial-wellness players (Origin, BrightPlan, SmartDollar) own one axis; biomarker labs (Function, Neko) own another. No player owns the intersection where biomarker signal becomes financial-decision action — and HIFP's compounding moat lives at exactly that intersection.
2. Four-lane GTM structure produces $50–140M Y3 ARR at 25–40× consumer-platform multiple — Employer hyper-focus (T1) + Concierge active direct-license (T2a) + Partner-channel D2C via Consumer-Wellness Partnership rev-share (T2b) + Employer overflow leak-capture (T3). The tier structure defends the Series B/C valuation multiple that T1-only cannot: T1-only produces a $24–29M ARR / $200–300M pre-money story with concentration + lumpiness discounts; the four-lane mix produces a diversified $57M base / $142M premium story with 25%-not-55% concentration and consumer-platform (not enterprise-SaaS) multiples.
3. The founder trio uniquely retires four otherwise-fatal Series A DD questions — (a) can this team ship a regulated consumer AI product? (Brandon: dual Salesforce Certified Architect + Agentforce Partner Innovation Lab lead + 2× founder-operator with exits + Health Cloud + EHR/EMR integration precedent); (b) can this team access the concierge chain buyer set at exec level? (Fatima: Oracle Health + prior Salesforce H&LS + Microsoft H&LS + Allscripts + McKinsey Clinical CoE network reaches MDVIP + One Medical + Executive Health Group + PartnerMD at buyer level); (c) does the clinical thesis hold up under adversarial review? (Sindhu: MD physiatrist + MBA + concept originator + VP Clinical Product Strategy at Hyro + Salesforce Global H&LS clinical leadership); (d) has the team pre-empted the regulatory / IP / AUP extinction risks? (three-tier regulatory frame + A+B+C underwriting-judo mitigation ratified + Anthropic AUP verified PASS-preliminary-strong + IP counsel provisional filings queued).

Recommendation. Lead or follow the SAFE at $15M cap; institutional lead of the pulled-forward Series A at Q1–Q2 2027. The insight window is 12–24 months. Post-Aura/Oura IPO, the category will not remain unmapped.

§1 · Deal & corporate overview

1.1 · Round structure

SAFE seed ($2.5M target · $2.0M floor · $15M cap post-money) is the immediate ask. Cap and organic-fallback unchanged from prior draft; target + floor bumped $500K each per 2026-09-11 trio direction to fund the 3rd founding engineer + HIPAA infrastructure baseline + Epic sandbox access + advisor-board budget (§1.3 rationale). Structured to pivot to Series A within 6–9 months of close. Organic-to-Series-A is the documented fallback at 90-day trigger per HIFP-safe-vs-organic-decision-matrix-v0.1 — the founder trio is committed to Series A path but preserves optionality if SAFE demand is soft.

Why $2.5M / $2.0M / $15M is the right shape. Sindhu's Friday concern was concrete: "is it a true MVP … or is it an idea" — will $2M actually fund the proof-of-integration that turns "sketch" into "investable data platform"? The $500K bump addresses that without breaking the SAFE→Series-A story: (a) same $15M cap signals discipline, no additional dilution; (b) floor still at $2M — the round works at either sizing; (c) $500K delta ladders cleanly to the four things Sindhu named as needed (3rd engineer, HIPAA infrastructure, Epic sandbox, buffer); (d) $2M vs $3M+ practical raise-difficulty at current valuation estimates makes this the sweet spot. See HIFP-open-questions-2026-09-11 §1 for the two alternates considered (YC-shape build round; MVP-as-idea with integration proof deferred).

Series A ($7–9M target, Q1–Q2 2027) is the primary raise. Led by health/longevity-strategic lane; AI-forward generalist opened as legitimate second lane. Both lanes' warm-intro paths are being sequenced by Fatima post-Karen general-counsel gate.

Living-standard floor built into SAFE: $250K/founder/year + health insurance. Ratified 2026-09-07 as non-negotiable SAFE condition. This is not a compensation preference — it is the mechanism by which two of three founders (Fatima day-job through July 2027; Sindhu Hyro cliff April 2027) can operationally commit to HIFP without personal cash-flow catastrophe. Removes founder-timing concentration risk that would otherwise gate diligence.

1.2 · Corporate structure

Entity: to be formed pre-SAFE close. Delaware C-corp, standard Series-A-ready structure. Cap-table planning includes founder equity + advisor pool + option pool + investor allocation.

Founder equity (pre-money, planned): founder trio holds majority equity pre-SAFE. Post-SAFE + post-Series A dilution modeled to preserve founder control through Series A close per standard trajectory.

Advisor pool: 3–5% reserved for advisor slots. Formalized 2026-09-12 as the advisors-via-SAFE-round posture (Brandon Message 2 to trio) — legal + financial + actuarial minds brought on as advisors funded through SAFE proceeds, not full-time hires, combined with Peter-lunch-shape validation discussions. Closes the v4 moats-strengthening ask surfaced Friday 2026-09-11 (Sindhu: "defensible in court") without requiring a fourth co-founder or full-time hire. Implements Fatima's three-mind pressure-test framework as advisor-board scoping.

Advisor-board archetypes (10 named candidates across 4 mind-types):

• Legal: Karen (Sindhu ex-Salesforce GC — coffee scheduling in flight per 2026-09-11); Alya (second-line)
• Financial: Cathy Lanning (FINS lead industry advisor at Salesforce — FINS-equivalent of Fatima's HLS role; same-shape asset, opposite domain — Sindhu-proposed 2026-09-11)
• Actuarial: Fatima's contact from Friday 2026-09-04 (retained as placeholder per 2026-09-07 alignment)
• Longevity + healthcare-operator: Romi Chopra (CEO MIMIT Health, Chicago — Fatima seeing at Dreamforce week of 2026-09-14)
• Consent-model expert: Kristen Valdes (b.well founder — dual-angle: consent-model consultation + potential b.well partnership contingent on funding; framing locked at Friday check-in)
• Investor-shape early advisors: Julie Yu (a16z Bio+Health, Katie intro); James Lakes (diversity-of-investments); Frisk Cressy (James Lakes intro); Tara Bishop (Hyro-portfolio conflict flagged and waved off by Fatima)
• Parked, non-US: Arundhati (former State Bank of India head — US-first scope holds)

Advisor-cost budget: ~$100–200K of SAFE proceeds across advisor honoraria + equity grants over the 16-month runway (indicative; individual engagements are one-shot moats-read consultations vs. ongoing advisory-board seats). Included in §1.3 use-of-proceeds.

Option pool: standard 10% pre-Series-A expansion targeted for post-close. Founding-engineering recruiting motion begins pre-SAFE per Ledger §6.1 reclassification.

1.3 · Use of proceeds

SAFE proceeds sequenced against the 16-week compressed MVP timeline (per HIFP-build-engineering-plan-v4, which supersedes v0.1 timeline-compression cut-sheet):

Total SAFE deployment ~$2.0M base scenario · $2.5M full ask. Executes 6–9 months of runway supporting SAFE → Series A pivot with organic-fallback documented at 90-day trigger.

MVP scope statement (locked 2026-09-12 per HIFP-build-engineering-plan-v4 §1): MVP = concept-proof + T2a chain-1 pilot + one clinical-import path proven end-to-end on test data. Series-A milestone = multi-chain HIPAA-hosted production + banking-tier security. The bump funds team + advisors + HIPAA infrastructure — NOT scope expansion. Message-1 to trio (thumbs-upped by Sindhu via DM): "We can increase the scope, but should try to keep it tight and also ladder into the series A milestone (multi-chain HIPAA-hosted production integration + banking-tier security) for Series A. Keeps us honest, doesn't overpromise and also a $2m SAFE round will be MUCH easier than $3M+ at current valuation estimates."

1.4 · Timeline

• Week 0 (SAFE close): Brandon full-time within 4 weeks. Founding-eng recruiting motion active pre-close.
• Weeks 1–16: compressed MVP build per HIFP-timeline-compression-cut-sheet-v0.1. Planning Agent + Plan-Delta + Coverage Navigator + Household + shareable summary + Stripe billing + T1 employer-tier product + T2a concierge chain 1 SMART-on-FHIR integration.
• Weeks 8–20: Karen briefing lands; IP provisionals file; market-signal lunches begin; T2a chain 1 conversations open (Fatima warm-intro).
• Weeks 12–24: first paying customers (D2C Plan Premium via Stripe from Day 1 · T2a chain 1 pilot); Fatima transitions when SAFE-covered seat funded.
• Months 6–9 (Q1–Q2 2027): Series A pitch cycle. Health/longevity-strategic lead + AI-forward generalist parallel warm-lane.
• Sindhu Hyro cliff: April 30 2027 (quarterly thereafter per Sindhu on-record correction 2026-09-11; was "annually"). Transition-earlier optionality documented if investors flag founder-timing concentration.
• Fatima full-time gate: July 1 2027 (fiscal-year hook + vesting). 4-week transition possible only after July 1 2027, not immediately at SAFE close if SAFE closes pre-July (Fatima clarification 2026-09-11). Fatima high-availability part-time carries the entire 16-week MVP window; full-time transition post-July-1.
• POC LIVE 2026-09-12 at hifp-poc.pages.dev (Cloudflare Access, NDA-only): three demoable persona surfaces — user (D2C, T2b lane demo) · practice (T2a lane demo) · employer benefits-admin (T1 lane demo — NEW 2026-09-12). Full inventory in HIFP-build-engineering-plan-v4 §2.

§2 · Value proposition · product · solution · technology

2.1 · What HIFP is

HIFP is a dual-surface consumer platform, AI-native at the user layer and actuarial under the hood, that computes and monitors biomarker-informed financial-planning decisions for HNW households approaching or in decumulation (target age 45–70, extending into the 70s and 80s for elderly-longevity / quality-of-life planning). Household aggregation is first-class; physician and advisor are in the loop where advice-shaped output would occur; the surface is user-primacy-first, not carrier-BD or fiduciary.

Public positioning line (Fatima 2026-09-11, ratified by Sindhu): "A financial concierge married to a medicine concierge — one plan, two experts, built around you." Live on POC landing as of 2026-09-12. Serves T2a Concierge active-direct lane as primary framing and grounds the T1 Employer benefits pitch (spouse + dependent + AARP-age extension) with a human-scale metaphor.

2.2 · Three flagship product primitives (MVP)

Planning Agent. Scoped tool-use LLM agent that computes stratified planning scenarios given household inputs. Bounded tool calls to the Planning Engine (Monte Carlo scenario runner + LTC-onset model + safe-withdrawal-rate calculator + coverage-gap analyzer). Advice-Boundary Classifier passes or blocks every rendered response. Anthropic Fable 5.1 primary production model (Source Log VERIFIED); OpenAI GPT-5 fallback.

Plan-Delta monitor. Continuous surveillance of user's biomarker + wearable + record data streams plus (extended 2026-09-11 per Fatima + Sindhu check-in) credit score · financial background · employment status · HENRY-segment markers — the full health-plus-financial signal envelope. When a material trajectory shift is detected (HRV decline, Function panel abnormality, cognition-screen inflection, credit-score movement, employment-status change), the monitor re-runs the plan and surfaces "three decisions worth revisiting" — never a specific investment or clinical recommendation, always a decision reframe. This is the compound value proposition: annual planning tools miss inflection points; Plan-Delta catches them across both health and financial signal domains. Financial-signal set is live in the POC at /plan as of 2026-09-12 with consent-scoped opt-in per category.

Coverage Navigator. User-side advocacy surface (not carrier BD channel). Three functions: (a) portability warnings when user's employer benefits or private coverage transitions, (b) coverage-gap identification across household + employer + Medicare + supplemental, (c) comparative-quote question-asking prompts. Explicitly NOT: fiduciary; not investment advice; not carrier data-flow channel.

2.3 · Foundational primitives

• Household plan surface with per-user Plan-Delta + joint scenarios (housing-timing, cognition-decline joint modeling, LTC purchase optimization across two lives)
• Shareable coverage-navigator summary (single-page, no-auth teaser view) — enables T2a practice-referral viral loop
• Practice-side aggregated cohort dashboard + AI-generated pre-visit brief — physician sees cohort trajectories, NOT individual patient outputs unless user shares
• AI-generated advisor brief — user exports HIFP output to their existing eMoney-using RIA at user discretion
• Household + share-role expansion (3→8 roles shipped in POC 2026-09-03)

2.4 · Four compounding moats

None transpilable at speed. Each earns IP protection separately.

1. Advice-Boundary Architecture. Model-output classifier + Boundary-Integrity mechanic + Ethical Framework enforcement. Any competitor with an LLM API can ship v0.1 of "biomarker planning" — they cannot ship the boundary architecture without independently reasoning through the classifier design, adversarial test corpus, and physician-in-the-loop mechanic. Estimated replication time: 12–18 months. Publication of the Advice-Boundary Whitepaper is IP-gated by publication-sequencing constraint (provisional filings first).
2. Coverage Navigator IP. Data-scope architecture + contractual firewall + partner-category-reshape from insurance-partner to Coverage-Navigator is a category-defining posture most competitors will fumble because the tempting insurance-BD lane is too economically obvious. HIFP's structural refusal to route data toward carrier underwriting decisions is the moat.
3. Consumer-Wellness Partnership rev-share channel compounding. Once Function ships the integration, they promote HIFP in perpetuity at ~zero marginal cost. Y1 partnership work produces Y2–Y5 near-free acquisition. Business Plan models T2b CAC as declining over time — unlike enterprise sales CAC.
4. Clinician-network credibility from T2a. Landing 20+ concierge practices in Y1 gives HIFP a clinician-adjudicated credibility story no benefit-consultant-led competitor (Alight, Fidelity Health) can match. The adversarial-test-corpus workflow requires this direct clinical relationship anyway; T2a monetizes it.

2.5 · Technology posture

• AWS production infrastructure (ratified 2026-09-07 with "unless disproven by later design" clause)
• Anthropic Claude / Fable 5.1 primary production model; OpenAI GPT-5 fallback. Both AUP-verified PASS-preliminary-strong (see §5 Risks); wellness advice exclusion (per Anthropic AUP direct-fetch verification) gives HIFP product-design latitude on biomarker-wellness framings
• SMART-on-FHIR for practice-portal integration (MDVIP + One Medical Premium + Executive Health Group + PartnerMD at MVP; four chains via SMART-on-FHIR variance)
• Clerk + WorkOS for auth + SSO
• Stripe billing pulled into MVP (locked 2026-09-07 as Hustle Plan Lane 1 enabler) — enables D2C Plan Premium live from Day 1
• b.well individual-access health-record aggregator (H1 addition) — analog to Kubera on wealth side; lets users pull records without going through concierge portal
• Kubera wealth-aggregation partnership (H1 primary launch); Empower on BD track for H2; Plaid deferred (HIFP will never integrate directly — user-primacy constraint)

2.6 · What HIFP will not do (structural refusals)

Explicit refusals matter for regulatory + trust positioning. HIFP is not: (a) a fiduciary; (b) an insurance seller; (c) a clinical intervener; (d) an employer-side individual-data-sharing conduit; (e) a carrier-underwriting data pipeline; (f) a white-labeled T2a service; (g) a paid-D2C-acquisition motion; (h) a T3 outbound-sales motion. These are structural, not negotiation positions.

§3 · Founding team & DD quality

3.1 · The trio and what each closes

Brandon Stauber — CPO/CTO through Series A. Currently Director, Partner Innovation Engineering at Salesforce (April 2021–present) · Salesforce Agentforce Partner Innovation Lab lead. Dual Salesforce Certified Architect (System + Application) + Salesforce AI Associate. 2× founder-operator with exits (iNetEvents 1999→2004 · The Wine Spies 2007→2012). Regulated-industry technical architect with prior Health Cloud + EHR/EMR integration precedent.

Closes: (a) product ownership from POC through Series A; (b) regulated-consumer-AI ship credibility — retires the "can the team ship a regulated AI product?" DD question; (c) chain-side technical integration (SMART-on-FHIR expertise + Salesforce partner-ecosystem BD network); (d) prior-startup operating history and demonstrated commercial exits.

Dr. Sindhu Pandit MD MBA — CCO of HIFP (adopted by non-dissent 2026-09-07, modifiable). Currently VP, Clinical Product Strategy at Hyro (conversational AI in healthcare) — title precision confirmed 2026-09-08. Formerly Clinical Leader at Salesforce Global Health & Life Sciences. MD physiatrist, MBA SMU.

Closes: (a) clinical concept validity — conceived the biomarker-informed planning thesis end-to-end; (b) physician-community access — Hyro + prior Salesforce H&LS clinical relationships + boutique-practice pipeline; (c) concept-to-clinical-validation execution — active author on stratified back-tests + adversarial-test-set clinical adjudication; (d) Ethical Framework v0.1 authorship (Sindhu owns full expansion within 14 days of 2026-09-07 alignment).

Dr. Fatima Paruk MD — prospective CEO. Currently senior health-leadership at Oracle (exact title + preferred bio phrasing owed pre-external-distribution — P0 blocker per HIFP-open-questions-2026-09-11 §8.1; single-Slack-message to close). Formerly SVP & CHO Salesforce Global H&LS · McKinsey Clinical CoE lead · Microsoft H&LS CMIO · Allscripts CMO. Additional context surfaced 2026-09-11: active AARP involvement + longevity / quality-of-life planning specialty — extends HIFP's addressable customer archetype into the 70s and 80s elderly-longevity segment.

Closes: (a) health-strategic distribution — network reaches MDVIP + One Medical Health + Executive Health Group + PartnerMD at buyer level; (b) CEO gravitas + investor room (health/longevity-strategic warm-lane); (c) F500 CHRO + regulatory-counsel relationships (unblocks Variant D + Karen briefing delivery); (d) AARP + elderly-longevity positioning credibility — Sindhu's Friday note: "you need to, your position with the AARP, how you've been so active in that space and really thinking about longevity, like and quality of life planning."

3.2 · Team complementarity — why the trio is more than the sum of its parts

Each founder retires an otherwise-fatal Series A DD objection that the other two would not close alone:

• Without Brandon, the team fails the "regulated consumer AI ship" DD line. Sindhu + Fatima are clinicians + operators; neither has the current dual-cert architect + Agentforce PIE lead + prior consumer-startup exit track record that convinces AI-forward generalists.
• Without Fatima, the team fails the "warm-intro to concierge chain buyer + F500 CHRO + health-strategic investor" access DD line. Brandon + Sindhu have technical and clinical credibility; neither has the CEO-gravitas exec-network Fatima brings.
• Without Sindhu, the team fails the "clinical concept validity + adversarial-test-set adjudication" DD line. Brandon + Fatima can operate; neither is the physician-scientist who conceived the thesis and can own back-test methodology.

This is not standard three-founder team-page casting. It is functionally MECE across the four DD questions Series A investors ask health-tech / consumer-AI companies.

3.3 · DD quality — the "how thoroughly has this team thought through what could go wrong" test

Per a16z Julie Yoo's stated evaluation criterion for early-stage health-tech investment: "the vast majority of what we index on is the founder, and how deeply they've thought through what could go right and wrong." HIFP's DD-quality signals are structural, not incidental:

• Source Log (HIFP-source-log) — every named factual claim in the artifact package tracked with source + verification status + last-checked date. Recent web-research pass (r2, 2026-09-07) verified 17 items including WA MHMDA + IL GIPA + Florida HB 1189 + NAIC AI Bulletin + Function Health + MDVIP + Neko + Genworth + Fidelity + Boldin + Aura/Oura + John Hancock Vitality + Galleri + Anthropic AUP.
• Verification Runbook (HIFP-verification-runbook-v0.1) — explicit human-verification protocols for every claim requiring direct outreach (PACER + practice patient counts + partner pricing + regulatory statute numbers).
• Life-Insurance Judo Memo (HIFP-life-insurance-judo-memo-v0.1) — 2026-09-04 Fatima flagged the reverse-judo underwriting risk as "could be existential for us." Weekend homework produced a 15K-word memo with four mitigation options. Trio adopted A+B+C 2026-09-07. Underwriting-partner path rejected outright. Insurance-data-outbound veto is standing.
• Red Team v3 (HIFP-red-team-v3) — 20 adversarial threats surfaced pre-external-review. T3 (frontier-LLM AUP exposure) verified 2026-09-08 to PASS-preliminary-strong via direct Anthropic AUP fetch + OpenAI secondary-source triangulation.
• General Counsel Briefing (HIFP-general-counsel-briefing-v0.1) — comprehensive briefing document prepared for Karen (Sindhu's ex-Salesforce GC, retired) to pressure-test the regulatory + IP posture from a plaintiff-attorney adversarial angle. Load-bearing pre-external gate.
• Founder Contingency Analysis (HIFP-founder-contingency-analysis-v0.1) — 2-of-3 founder scenarios modeled with new-CEO network-recovery lever documented.
• 90-day decision framework — Brandon has NOT unconditionally committed; six pre-committed gates decide go/no-go (per founder-side discipline). This means the team is intellectually honest about the shelf conditions, not motivated-reasoned into the raise.

The composite signal: this trio has already thought through the risks a DD partner would surface, produced written analysis, and reshaped the strategy where the risk was structural. Underwriting-judo A+B+C is the clearest example — a risk surfaced Friday became a category-defining reshape by Monday, not a defensive dismissal.

3.4 · Advisor board (in formation)

Formalized 2026-09-12 as the advisors-via-SAFE-round posture — legal + financial + actuarial + operator advisors funded through SAFE proceeds (§1.3 advisor-board budget line), not full-time hires. Implements Fatima's three-mind pressure-test framework (2026-09-11 proposal, ratified by Sindhu) as advisor-board scoping. Closes the moats "defensible-in-court" ask surfaced Friday 2026-09-11 without requiring a fourth co-founder or full-time hire.

Candidates (10 named across mind-types) — see §1.2 for consolidated table:

• Legal mind: Karen (Sindhu ex-Salesforce GC, retired mentor — coffee scheduling in flight per 2026-09-11 in-meeting text); Alya (second-line)
• Financial mind: Cathy Lanning (FINS lead industry advisor at Salesforce — the FINS-equivalent of Fatima's HLS role; same-shape asset, opposite domain; Sindhu-proposed 2026-09-11 as answer to the wealth-management gap)
• Actuarial mind: Fatima's contact from 2026-09-04 (placeholder per 2026-09-07 alignment)
• Longevity + healthcare-operator mind: Romi Chopra (CEO MIMIT Health, Chicago — Fatima seeing at Dreamforce week of 2026-09-14; potential investor-shape as well)
• Consent-model expert: Kristen Valdes (b.well Founder & CEO — dual-angle: consent-model consultation + potential b.well partnership contingent on funding; framing locked at Friday check-in)
• Investor-shape early advisors: Julie Yu (a16z Bio+Health, Katie intro); James Lakes (diversity of investments); Frisk Cressy (James Lakes intro); Tara Bishop (Hyro-portfolio conflict flagged, waved off by Fatima)
• Parked non-US: Arundhati (former State Bank of India head — US-first scope holds)
• Earlier candidates retained: Michelle Feinstein (Fatima intro), Dan Conners (NVIDIA partnerships, Fatima intro), David / David Ventures (Sindhu intro)

Slot commitments: Medical Lead (0.5% equity) at Series A close; ASA-LTC actuary is Series A hire, not advisor. Advisor-board budget of ~$100–200K deploys against honoraria + equity grants over the 16-month runway.

3.5 · Founding engineering

Recruiting motion begins pre-SAFE. Target profile: full-stack + SMART-on-FHIR familiarity + LLM tool-use experience + regulated-industry background helpful. No named candidates as of memo date; motion runs concurrent with SAFE outreach.

§4 · Market opportunity · TAM · customer overview

4.1 · Aggregate market at play

HIFP addresses a novel intersection of three markets that no single player currently spans:

• US self-funded employer benefits market — ~$100M covered lives across ~4,500 self-funded employers (KFF 2024). HIFP T1 hyper-focus is a ~500–1,000 employer sub-segment (self-funded × long-term-equity comp — Salesforce-shape); T3 leak-capture addresses adjacent ~15,000 broader employers with ~90M covered lives. Combined T1+T3 addressable universe: ~16,000 employers, ~115M covered lives.
• US concierge / DPC market — ~1,500 practices, ~5–8M patient lives (MDVIP ~450K across 1,300–1,400 physicians · One Medical ~900K · independent DPC ~4–6M). HIFP T2a serviceable in 3-year window: 200–400 practices, ~1.5–3M patients.
• US HNW household D2C market — ~5M households with $1M–$25M investable assets. HIFP reaches D2C only through T2b Consumer-Wellness Partnership channel (Function 350K + Neko growing + Aura/Oura 5M + biomarker labs long tail + wearables) — NO standalone D2C GTM motion.

Serviceable and landable at Y3 base case: ~50 employers combined (T1+T3) · 30 concierge practices · 500K partner-channel-acquired users. Base-case revenue ~$57M; premium-case ~$142M.

4.2 · Customer archetype — anchor scenario

A 62-year-old HNW couple with $4M investable assets and 8 dated Function Health panels between them has more financial-decision-quality data than their advisor, their physician, or their employer can currently ingest, interpret, or turn into action.

Concrete decision-quality gaps HIFP closes:

• LTC purchase timing tightens from a 15-year band to a 3-year band. Biomarker + wearable signal + family-history + cognition-screen data narrow the LTC-onset probability window. Boldin, eMoney, RightCapital, MoneyGuidePro model LTC as a line item; none ingest the signal.
• Coverage gaps compound silently. Long-term-care insurance persistency is ~25% at 30-year mark. Medicare Advantage covers Galleri MCED with copay from earliest MA plans (Priority Health Jan 2026); Medicare reimbursement begins 2028 per Feb 2026 Coverage Act. Employer disability + supplemental interact with private coverage in ways households do not model. Coverage Navigator surface fills this without becoming a carrier BD channel.
• The trust asymmetry is severe. Concierge medicine's ~500K–1M HNW patients have (a) longitudinal biomarker data already being collected, (b) an existing consent relationship with a physician who sees them 4–8 times a year, and (c) documented willingness to pay $2K–$25K/year cash for cash-pay medicine. That trust asymmetry does not exist in the RIA / advisor channel — HIFP wins by meeting users where trust already lives.

4.3 · Buyer-side map by tier

Y3 base mix 63/16/13/8. Top-5 concentration at base ~25% (vs T1-only ~55%). Total user count at base ~1M+.

4.4 · Category position — no incumbent worth naming today

• Genivity/Lumiant — v1 competitive framing. Distressed at 7 employees mid-2026 (reconfirmed via 2026-09-07 web-research pass); no new funding since March 2023 $3.5M seed; HALO product remains self-report-only 3+ years post-acquisition. Possible tuck-in target post-Series-A ($5–15M cash + stock likely acquires).
• Financial wellness players (Origin · BrightPlan · SmartDollar · Fidelity FW) — own generic financial wellness axis. Do not ingest biomarker signal. Under-priced at $2–5 PMPM vs HIFP's $4–6 base / $6 premium tier that requires demonstrable clinical or actuarial ROI evidence.
• Biomarker labs (Function · Neko · Superpower · Prenuvo · HLI) — own biomarker consumer axis. Do not do financial planning. Function $2.5B, 350K members; Superpower $199 founding tier → $349 Sept 1 2026; HLI five-tier ladder $599 → $25K. All are P0 Loop C partner-channel targets, not competitors.
• Wearable-longevity (Aura/Oura · Whoop · Apple Health) — own continuous physiologic signal axis. Aura/Oura S-1 filed Sept 3 2026 ($11–16B valuation range, 5M members, $1.4B TTM revenue). P1 Loop C partner-channel target — and simultaneously the highest-credibility potential competitor post-IPO (see §5 Risks).
• Benefits-consultant-led (Alight · Fidelity Health · WTW · Mercer) — own employer-benefit distribution. Cannot show clinical adoption. HIFP's T2a clinician-network credibility moat is exactly the response.
• RIA / advisor-tech (eMoney · RightCapital · MoneyGuidePro · Envestnet · Orion) — own advisor-side planning software. Do not have consumer + biomarker surface. Y2 Variant A OEM optionality per POV v4 §14.

4.5 · Why now — five converging signals

1. Biomarker labs at $199–$599/yr entry point. Superpower founding tier $199 through Aug 31 2026 → $349/yr from Sept 1 2026 · Function $365/yr · HLI Genomics for All $599 (new Aug 2026 entry-point).
2. Frontier LLMs able to reason about longitudinal multi-source health + financial data. Anthropic Fable 5.1 confirmed Sept 1 2026 as production model. AUP verified.
3. SMART-on-FHIR adoption across concierge chains enables practice-portal integration at MVP scope.
4. Aura/Oura filed S-1 Sept 3 2026 at $11–16B range signaling wearable-longevity IPO market maturation.
5. Fidelity + Genworth 2026 cost updates surfacing decumulation-cost inflation to a broader HNW audience — Fidelity 2026 estimate $185,500/individual + $371,000/couple (up 7.5% YoY); Genworth 2025 assisted living $74K/yr + nursing home $115–130K/yr + home care $80K/yr.

Convergence window: approximately 12–24 months before the category is mapped by an existing wearable-longevity IPO acquiring biomarker + fintech, or a benefits-consultant conglomerate white-labeling a similar surface. HIFP's structural moats (Advice-Boundary + Coverage Navigator + clinical credibility + partner-channel compounding) are 12–18 months to replicate independently — but only if built before the window closes.

§5 · Strategic signals — validating events + risks + watch triggers

5.1 · Validating strategic signals (tailwinds)

• Aura/Oura S-1 filed Sept 3 2026 · $11–16B range · 5M members · $1.4B TTM revenue. Category-validating; establishes wearable-longevity IPO market. HIFP's T2b Loop C P1 wearable partnership becomes strategically load-bearing (see §5.3 Aura risk).
• Function Health $2.5B valuation, $298M Series B led by Redpoint (Nov 2025), 350K members, price dropped $499 → $365. Category-validating on biomarker consumer scale + price accessibility.
• Neko Health $700M Series C (Lightspeed + O.G. Ventures, July 2026), NYC-first US launch, 2,000+ high-res skin images per scan. Category-validating on high-touch preventive-health consumer willingness-to-pay.
• Galleri MCED Coverage Act (Feb 2026), Medicare reimbursement 2028. Category-validating on regulatory recognition of longitudinal preventive-signal value.
• Fidelity 2026 healthcare retirement cost estimate up 7.5% YoY to $185,500/individual + $371,000/couple. Decumulation-cost inflation surfacing at HNW awareness threshold — HIFP's addressable pain sharpens.
• Salesforce H&LS reorganization + Oracle Health investment. Both events created senior-clinical-executive availability the trio benefits from (Sindhu ex-Salesforce H&LS, Fatima Oracle Health-adjacent + prior Salesforce H&LS).
• Anthropic AUP explicitly excludes wellness advice (sleep/stress/nutrition/exercise) from healthcare high-risk category (verified 2026-09-08 direct fetch). HIFP has product-design latitude on biomarker-wellness framings — an unexpected upside signal.
• b.well Founder Kristen Valdes named EY Entrepreneur of the Year 2025 Mid-Atlantic. Consent-model reference category is receiving industry recognition. b.well is HIFP's H1 individual-access health-record aggregator partnership target.
• Genivity/Lumiant distressed at 7 employees mid-2026. v1 competitive incumbent framing is retired; category is un-defended.

5.2 · Risks + mitigations (priced)

HIFP has surfaced and priced eight risks in HIFP-red-team-v3 + HIFP-life-insurance-judo-memo-v0.1 + HIFP-POV-v4 §12. Three extinction-class and one existential-class are fully resolved; five active. Summary:

5.3 · Aura/Oura post-IPO competitive risk (elevated 2026-09-08) + Gallagher/Marsh/Aon second vector (added 2026-09-11)

Second competitive vector surfaced Friday 2026-09-11: benefits-consultant brokerages (Gallagher / Marsh / Aon) already run health-and-wealth-bucket offerings for enterprise clients. Sindhu's Friday note: "still not entirely convinced they're not a competitor or a frenemy." Fatima's leaning: "complementary … we need that really strong open partnership model."

HIFP posture — competitive/complementary/partner/different framing (Brandon 2026-09-10 analysis):

• Competitive layer: Gallagher-shape brokerages own the benefits-committee relationship HIFP wants for T1 employer lane. Direct competition on the sale of what goes into the plan.
• Complementary layer: HIFP is the biomarker-plus-financial-planning consumer surface inside the benefits stack; Gallagher is the broker curating and negotiating the stack. Non-substitutable at the underlying-function level.
• Partner-model: Gallagher/Marsh/Aon are natural distribution channels for T1 lane — one broker relationship unlocks a portfolio of employer clients. Benefits-consultant channel added to HIFP-gtm-tier-strategy-v0.1 §6.1 T1 candidate list.
• Different-audience layer: Gallagher sells to the CHRO/CFO; HIFP is used by the employee + family. Different buyer, different user, different value moment.

Mitigation: Partnership-first posture through Karen briefing → NDA → broker-conversation sequence. If broker adopts HIFP as a portfolio-offering line item, competitive vector converts to distribution channel. Watch trigger: any Gallagher/Marsh/Aon announced acquisition or partnership with a biomarker lab or consumer-longevity company.

5.3.1 · Aura/Oura risk detail

Aura/Oura's S-1 cuts both ways. It validates the category (§5.1) AND creates the most credible potential competitor at the biomarker-plus-financial-planning intersection HIFP's Executive Summary claims "no incumbent worth naming." Post-IPO capitalization enables three competitive moves:

1. Move up-stack into biomarker-plus-financial-planning intersection directly
2. Acquire a biomarker lab (Function at $2.5B or Neko at $700M+ Series C) for full-stack coverage
3. Partner with a fintech (Wealthfront · Personal Capital / Empower · Robinhood) to launch a competing offering under a trusted-consumer-brand

Mitigation (three layers):

• Architectural — not replicable by acquisition. HIFP's user-primacy + clinician-mediated architecture is structural. A wearable company acquiring a biomarker lab and bolting on a fintech creates a data-aggregation product; it does not create a Coverage Navigator + Advice-Boundary + physician-in-the-loop system. Replication requires 12–18 months of independent architectural work.
• Positioning — reframe Aura as channel, not competitor. T2b Loop C explicitly positions Aura/Oura as P1 channel partner. If Aura signs the partnership before considering up-stack expansion, the competitive move is much harder to make later. This makes the P1 wearable partnership strategically load-bearing, not just tactically opportunistic.
• Optionality — if Aura moves up-stack anyway, HIFP shifts positioning to Aura-as-data-source. HIFP does not need to defeat Aura; HIFP needs to be the credible planning-decision layer that Aura customers use. Loss condition is Aura owning the intersection outright; win condition is Aura's members flowing to HIFP through partnership or direct signup.

Watch triggers. (a) Aura acquires or partners with Function/Neko/HLI; (b) Aura hires C-level fintech / financial-planning leadership; (c) Aura's post-IPO roadmap includes any "financial planning" or "life planning" language.

5.4 · Legal validation — areas held for Karen review

These are open questions HIFP is explicitly holding for Karen (general counsel briefing) before external representation. The list is designed to be exhaustive: anything with a legal dimension that is not yet settled sits here, not in the memo body as fact. Karen briefing (Ledger §3.24 · Sindhu owner) is the standing pre-external gate; the six items below are the current review packet.

Discipline gate. Standing rule since 2026-09-07 alignment: no external investor representation of any claim in this table's "assumption held today" column until Karen has reviewed the relevant packet. Karen briefing (HIFP-general-counsel-briefing-v0.1) is the load-bearing pre-external step; the six items here are the current review scope. Sindhu owns Karen scheduling.

5.5 · Traction signals to date (pre-SAFE, evidence-of-concept)

• Working POC LIVE at hifp-poc.pages.dev (Cloudflare Access, NDA-only, deployed 2026-09-11; v4-alignment updates shipped 2026-09-12) — three demoable persona surfaces: User (D2C · T2b lane demo) with dual-concierge landing + AARP archetype + Plan-Delta signal categories (health + financial) · Practice (T2a lane demo) with cohort dashboard + SMART-on-FHIR integration status · Employer benefits-admin (T1 lane demo — NEW) with self-insured metrics + family-attach take-rate + underwriting-firewall callout + Gallagher/Marsh/Aon benefits-consultant channel positioning. Ledger §3.49-3.51 tracks. Runbook: HIFP-poc-hosting-runbook-v1. Investor-ready demo path: hifp-poc.pages.dev → DemoModeMenu (bottom-left) → Employer view / Physician view.
• 17-artifact + 9-HTML canvas including POV v3.1 (long-form strategic) · POV v4 draft-02 (canonical v4 with gap-audit) · Investor Deck v3 (14-slide walk) · GTM Tier Strategy v0.4 (~10K-word analytical spine) · GC Briefing v0.1 · Life-Insurance Judo Memo v0.1 · Ethical Framework v0.1 skeleton · Chain Partnership Playbook v0.1 · SAFE Readiness v0.1 · Source Log r2 (VERIFIED across 17 items via 2026-09-07 web-research pass) · Verification Runbook v0.1 · Founder Contingency Analysis v0.1.
• Ledger of ~80 tracked open items with priority + owner + status. Ratification cadence documented across three trio sessions (2026-08-31, 2026-09-04, 2026-09-07) with Friday 2026-09-11 fourth session queued.
• Founder team ratified as CPO/CTO + CCO + prospective-CEO at 2026-09-07 alignment. Full-time transition timing locked (Brandon within 4 weeks of SAFE close; Fatima July 2027 pulled forward per SAFE-covered seat; Sindhu April 30 2027 cliff with transition-earlier optionality).
• Ethical Framework skeleton adopted by trio non-dissent 2026-09-07. Three commitments (User Primacy · Boundary Integrity · Transparency with Agency). Full v0.1 expansion owed within 14 days.
• Underwriting-judo A+B+C mitigation ratified — a Fri-flagged-existential-risk-Mon-ratified-A+B+C-mitigation cycle demonstrates trio's decision-cadence and adversarial-thinking discipline.

§6 · Financial diligence & investment

6.1 · Consolidated Y3 revenue model — three consistently-computed cases

Per HIFP-gtm-tier-strategy-v0.4 §5 methodology (each case applies same PMPM assumption across all four lanes; account counts held constant; PMPM assumption varies):

6.2 · Series B / C valuation implications

Consumer-platform multiple range 25–40× ARR at growth (before compression). Applied to Y3 ARR scenarios:

• Downside: $40M × 25× = ~$1B Series B pre-money
• Base: $57M × 25–30× = $1.4B–$1.7B Series B / early Series C
• Premium: $142M × 25–40× = $3.5B–$5.7B Series C valuation range

For comparison, HIFP T1-only pure play would produce $24–29M ARR at Y3, priced against enterprise-SaaS multiples (10–15× ARR) → $250–450M Series B pre-money. The four-lane structure adds $1B+ in Series B / early Series C valuation for essentially the same T1 hyper-focus discipline plus lightweight T2 + T3 additions.

6.3 · Unit economics per lane

CAC trajectory over time — T2b partner-channel CAC is modeled as declining (channel-compounding) rather than steady-state, unlike T1 sales-team CAC. This is the mechanism that turns T2b from a small ARR contributor into a meaningful margin-expansion lane over Y3–Y5.

6.4 · Lane sensitivity — what if a lane delivers zero (at base case)

• T2b zero (no Consumer-Wellness Partnerships materialize): ARR drops from $57M to ~$50M; user-count story loses ≥50% weight → Series B multiple compresses ~$100M. Accretive lane; not load-bearing.
• T3 zero (no marketing leakage inbound): ARR drops from $57M to ~$52M; no strategic impact. Pure upside; zero risk from underperformance.
• T2a zero (concierge practice motion fails): ARR drops from $57M to ~$48M; but smoothness + clinical credibility loss is severe — Q/Q growth predictability degrades, moat weakens. Structurally important; not just additive.
• T1 zero: Fatal. There is no HIFP without T1.

6.5 · Comparable transactions + valuation anchors

Health-tech / consumer-fintech Series A/B comparables (2025–2026):

• Function Health — $298M Series B at $2.5B valuation (Redpoint, Nov 2025) · 350K members · ~$150M ARR implied at $365/yr average · ~17× ARR multiple
• Aura/Oura — S-1 filed at $11–16B range · 5M members · $1.4B TTM revenue · ~8–12× revenue multiple (public-market entry)
• Neko Health — $700M Series C (Lightspeed + O.G., July 2026) · NYC US launch · valuation ~$1.5–2B range implied
• Boldin (financial planning) — smaller, private; $144/yr consumer tier · $2,800/yr advisor tier; category-adjacent, sub-scale to Aura
• Livongo/Teladoc (pre-Teladoc) — pre-IPO consumer-clinical hybrid; valuation trajectory shows category-defining companies compound multiple over time

HIFP's Y3 base case ($57M ARR at 25–30× → $1.4–1.7B) sits between Boldin's sub-scale reference and Function's current mid-scale reference. HIFP's Y3 premium case ($142M at 25–40× → $3.5–5.7B) sits between Function's current valuation and Aura/Oura's public-market range.

6.6 · Return scenarios for Series A lead

Assume Series A closes at $7–9M raise / $35–45M post-money → Series A lead owns 15–25% at close. Standard 3-year exit projection:

• Downside Series C at $1B pre-money: Series A lead 15–25% stake worth $150–250M · Series A lead invested $3–5M → ~30–50× return
• Base Series C at $1.7B pre-money: Series A lead stake worth $255–425M · Series A lead invested $3–5M → ~50–85× return
• Premium Series C at $5B pre-money: Series A lead stake worth $750M–$1.25B · Series A lead invested $3–5M → ~150–250× return

Standard dilution assumptions (10–15% dilution per subsequent round) reduce these by ~30–40% by exit — still clearing the 10× minimum threshold for venture returns in downside scenario and clearing 100×+ in premium.

6.7 · What HIFP will do with capital (deployment logic)

SAFE proceeds fund the 16-week MVP + Karen briefing + IP provisionals + first customer traction (D2C via Stripe Day 1 + T2a chain 1 pilot + benefit-consultant channel scoping).

Series A proceeds fund: (a) product completion through H1 scope (T2b partner-integration surface + T3 Standard SKU + b.well aggregator + practice-portal chains 2–4), (b) BD team hires (T1 Employer AEs + T2a chain BD + T2b partnership manager), (c) actuarial + compliance hires (ASA-LTC lead + Medical Lead advisor + regulatory counsel retention), (d) adversarial-test-set clinical adjudication at scale, (e) advisor-board build-out.

Not what capital funds: (a) paid D2C acquisition (structural refusal); (b) T3 outbound sales motion (kill criterion if T3 consumes >5% of team time); (c) insurance-carrier BD (structural refusal per underwriting-judo); (d) M&A pre-Series-C (unless HALO/Lumiant tuck-in materializes on obvious terms).

§7 · The ask + recommendation

Recommendation: lead or follow the SAFE at $15M cap. Series A lead is available at Q1–Q2 2027 pulled-forward window; institutional lead for health/longevity-strategic lane with AI-forward generalist parallel warm-lane structured to widen the room.

Three reasons the check is worth writing:

1. The insight window is 12–24 months. The intersection HIFP is building — biomarker-informed planning at the point of clinical trust + user-primacy + Coverage Navigator + partner-channel D2C — has no incumbent today. Aura/Oura's IPO validates the category and creates the credible potential competitor. Post-IPO, the intersection gets mapped. HIFP's architectural moats take 12–18 months to replicate; the head-start window is real but not perpetual.
2. The founder trio is a MECE fit to the four DD questions. Not a good team assembled by narrative. A team where each founder retires a distinct otherwise-fatal DD objection. See §3.2.
3. DD quality signals are structural, not incidental. Underwriting-judo A+B+C ratified in ~72 hours from Friday flag to Monday ratification (not a defensive dismissal, a category-defining reshape); Ledger discipline; Source Log verification; Red Team + Judo Memo + GC Briefing pre-external produced; Ethical Framework author owns the through-line document. The trio thinks like a partner would want the founding team to think.

Terms. SAFE at $2.0M target / $1.5M floor / $15M cap. Standard SAFE mechanics (no discount required; cap-only structure). MFN clause for early SAFE investors. Founder living-standard floor built into use of proceeds (not a preferential term, but a structural constraint enabling founder full-time transition).

Timing. SAFE close targeted 4–8 weeks from initial partner conversation. Series A pitch cycle opens Q1 2027, closes Q2 2027. First customer traction (D2C Plan Premium via Stripe live from Day 1 + T2a chain 1 pilot) targeted within 4 months of SAFE close.

What we ask of the Series A lead beyond capital. (a) Warm-intro to complementary Series A co-investor (health/longevity-strategic + AI-forward generalist), (b) advisor-slot Medical Lead recommendation from portfolio, (c) benefits-consultant channel introduction (Mercer, WTW, Aon), (d) health-strategic BD introduction (existing portfolio companies with concierge-chain or biomarker-lab positioning).

§8 · Companion artifacts + supporting analysis

Full supporting analytical spine available under NDA:

• HIFP-POV-v4 — canonical strategic point of view (mission-first, ~8K words, all v4-kit artifacts derive from this)
• HIFP-investor-deck-v4 — 14-slide investor walk (visualization companion to this memo)
• HIFP-gtm-tier-strategy-v0.4 — four-lane GTM analytical spine (~10K words; per-tier value props; three-loop viral reading; six-priority partner sub-classes; PMPM public-comps pressure-test; Appendix A premium case + Appendix B PMPM comps)
• HIFP-general-counsel-briefing-v0.1 — comprehensive briefing document for regulatory + IP pressure-test (Karen input; delivered by Fatima)
• HIFP-life-insurance-judo-memo-v0.1 — 15K-word underwriting-judo memo with four mitigation options; A+B+C ratified 2026-09-07
• HIFP-red-team-v3 — 20 adversarial threats surfaced pre-external-review; T20 + T3 resolved
• HIFP-source-log — r2 with 17 items VERIFIED via 2026-09-07 web-research pass
• HIFP-verification-runbook-v0.1 — human-verification protocol for every claim requiring direct outreach
• HIFP-ethical-framework-v0.1-skeleton — three commitments adopted; full v0.1 expansion owed by Sindhu within 14 days
• HIFP-chain-partnership-playbook-v0.1 — T2a chain BD execution playbook
• HIFP-SAFE-readiness-v0.1 — SAFE structure + closing checklist
• HIFP-safe-vs-organic-decision-matrix-v0.1 — organic-fallback decision matrix with 90-day trigger
• HIFP-timeline-compression-cut-sheet-v0.1 — 16-week compressed MVP sequencing
• HIFP-org-and-hiring-plan-v0.1 — org design + advisor slots + Series-A hires
• HIFP-founder-contingency-analysis-v0.1 — 2-of-3 scenarios with new-CEO network-recovery lever
• HIFP-model-fairness-protocol-v0.1 + HIFP-advice-boundary-spec-v0.1 + HIFP-security-architecture-v0.1 + HIFP-testing-framework-v0.1 + HIFP-compliance-foundation-v0.1 + HIFP-data-lifecycle-sla-v0.1 — foundation specs
• HIFP-ip-assessment-v0.1 — IP posture + provisional-filing scope

POC (24-route working prototype) demoable live under NDA.

§9 · Draft-02 gap surfacing (for partner review)

This memo intentionally surfaces open items so the partner reviewing it sees the state of decision-making, not a smoothed-over story. Draft-02 status: Friday 2026-09-11 check-in closed 5 items and opened 3 new ones; morning-of 2026-09-12 send opened the SAFE thumbs-up window; POC v4-alignment shipped 2026-09-12. Delta from draft-01 below.

9.1 · RESOLVED at Friday 2026-09-11 check-in (5 clean closes)

• ✅ GTM tier structure RATIFIED — four-lane (T1 Employer + T2a Concierge active-direct + T2b Partner-channel D2C + T3 Employer-overflow); Sindhu on record: "I am fine with those four areas."
• ✅ Dual-concierge positioning phrase adopted — "financial concierge married to a medicine concierge" (Fatima); shipped to POC landing 2026-09-12
• ✅ Delaware C-corp confirmed
• ✅ Kristen Valdes (b.well) framing locked — dual-angle consultation (consent-model expert + partnership contingent on funding)
• ✅ US-first scope reconfirmed — Arundhati parking-lotted, non-US advisors parked

9.2 · IN FLIGHT (status changed since draft-01)

• 🔄 Karen briefing — status: queued → in flight (Sindhu texted Karen live during Friday call to schedule coffee; sequence: coffee → briefing → GC intro; Alya sequenced second-line)
• 🔄 Fatima transition timing clarified — 4-week full-time transition possible only after July 1 2027 (was ambiguous in draft-01)
• 🔄 Sindhu cadence corrected — "quarterly thereafter" (not "annually") post-April-30-2027 cliff

9.3 · TOP DECISION — awaiting formal trio thumbs-up (Monday 2026-09-14 5pm PT silence-is-assent)

• 🎯 SAFE sizing at $2.5M target / $2.0M floor / $15M cap post-money — directionally adopted; formal ratification pending. Per HIFP-decision-log-2026-09-11 §1: silence-is-assent from Sindhu OR Fatima closes; explicit re-open from either party pauses v4-kit propagation. If ratified as expected, the ask in the memo header becomes final; if re-opened, memo header reverts to $2.0M/$1.5M/$15M with alternate-path discussion opened in §1.1.

9.4 · REMAINING gaps (Brandon-response owed pre-external-distribution)

• ⏳ Fatima exact Oracle title + preferred bio phrasing — P0 blocker on §3 team bios. Blocked-on-direct-call, not on documents. Single-Slack-message from Fatima closes. Per HIFP-open-questions-2026-09-11 §8.1. Blocks external distribution + Karen briefing read-ahead + advisor outreach + investor conversations.
• ⏳ Sindhu formal bio for §3 — companion ask to Fatima; asked in Brandon's 2026-09-12 AM send
• ⏳ Moats section "defensible in court" rewrite — Sindhu Friday standard: "defensible in court type of thing." Three-mind pressure test framework (financial + actuarial + legal advisors engaged early) is the shape; §7 propagation gated on advisor-board formation
• ⏳ Wealth-management advisor slot — Cathy Lanning archetype named as candidate (FINS lead industry advisor at Salesforce); outreach sequenced post-Karen coffee → NDA → conversation
• ⏳ Anthropic + AWS cost lines — Fatima 2026-09-11: "there's something there that we need to be thinking about there in the financial model." Unit-economics assumptions documented in HIFP-build-engineering-plan-v4 §7; specific line-item detail in §1.3

9.5 · Gated on Karen general-counsel briefing (Ledger §3.24, in flight)

• Final PASS on regulatory-language sections (§9 POV v4 three-tier frame)
• Final PASS on Red Team T3 AUP exposure
• NDA template for external distribution
• IP counsel referrals for provisional filings
• Hyro invention-assignment scope review (§12.8 Sindhu IP-assignment mitigation)

9.6 · Remaining founder-input asks (per HIFP-founder-inputs-2026-09-08 and Friday-check-in additions)

Sindhu (7 open): full Ethical Framework v0.1 expansion (14-day target 2026-09-21) · CCO title confirmation · clinical-network warm-intro map for T2a chains (MDVIP · One Medical Premium · EHG · PartnerMD) · IP counsel referrals via Karen · Neko + Aura post-IPO watch · chart-modal advice-boundary sanity check · Karen briefing delivery prep coordination

Fatima (7 open — §9.4 title P0 pulled out separately): Karen briefing delivery prep · employer sub-segment matrix (pursue vs list-and-park variants) · rev-share economics pressure-test (10–20% range from prior partnership experience) · named investor targets by lane (health/longevity-strategic + AI-forward generalist) · advisor intros (Michelle Feinstein + Dan Conners) · named actuary contact (§5.1) · "best financial planners" question-quality corpus contribution

9.7 · Owed downstream artifacts (v4 kit — propagation queue loaded, paused pending §9.3 SAFE thumbs-up)

• ✅ Build + Engineering Plan v4 — shipped 2026-09-12 (HIFP-build-engineering-plan-v4); supersedes v0.1 timeline-compression cut-sheet + hustle plan
• ⏳ POV v4 draft-02 — SAFE numbers + MVP-scope statement + AARP archetype + dual-concierge framing + Gallagher second-competitive-vector + moats-strengthening rewrite hook + advisor-candidate section
• ⏳ Investor Deck v4 (14-slide walk) — companion to this memo; shipping alongside draft-02
• ⏳ GTM Tier Strategy v0.4 → v0.5 — Gallagher/Marsh/Aon-shape added to §4.4 category-position map + §6.1 T1 benefits-consultant channel candidate list
• ⏳ Founder Inputs HTML — refresh to reflect Friday closes (b.well framing locked; Karen briefing in flight)
• ⏳ Three-Mind Moats Pressure-Test framework — new artifact operationalizing Fatima's Friday proposal
• ⏳ Product Design v4 (three primitive specs: shareable summary + T2b partner-integration surface + T3 Standard SKU)
• ⏳ Business Plan v4 (lane sensitivity + CAC declining model + Y4–Y5 projection)
• ⏳ Q&A v4 (preemptive T20 + T3 + "why not T1-only" + "isn't D2C fintech hard" + "isn't Aura your future competitor" + new: "how does Gallagher/Marsh/Aon fit")
• ⏳ Segment Messaging v4 (rewrite per GTM Tier Strategy §6.4 + dual-concierge line integrated)
• ⏳ GTM Plan v4 (sequencing per publication-sequencing IP constraint)
• ⏳ Value-Decision Memo v4 (Brandon personal; not distributed)

None of these gate a first-partner conversation. They gate the external distribution and Series A pitch cycle, which is Q1–Q2 2027 targeted. Between now and then, the trio is closing them systematically.

Version history

• v4-draft-02 · 2026-09-14 — Update reflecting Friday 2026-09-11 check-in ratifications + morning-of 2026-09-12 direction + POC v4-alignment shipped 2026-09-12. Deltas from draft-01: (1) SAFE ask bumped to $2.5M/$2.0M/$15M (directionally adopted; formal ratification pending); (2) §1.3 use-of-proceeds revised with 3rd founding engineer + HIPAA infrastructure baseline + advisor-board budget; (3) §2 dual-concierge positioning line added; (4) §2.2 Plan-Delta extended with financial signals (credit score · financial background · employment status · HENRY-segment markers); (5) §3.1 Fatima bio expanded with AARP/elderly-longevity positioning; (6) §3.4 advisor-board formalized via advisors-via-SAFE-round posture with 10 named candidates including Cathy Lanning archetype; (7) §5.3 Gallagher/Marsh/Aon second-competitive-vector added; (8) §5.4 traction updated — POC LIVE with three demoable persona surfaces including new employer benefits-admin; (9) §9 gap surfacing rewritten with Friday closes + in-flight items + Monday 5pm PT SAFE thumbs-up window + Fatima title/bio P0 blocker; (10) Companion list updated with HIFP-build-engineering-plan-v4 (supersedes v0.1 timeline-compression cut-sheet + hustle plan). Distributable pending SAFE ratification + Fatima title/bio close.
• v4-draft-01 · 2026-09-09 — Initial investment memo drafted for external Series A distribution. Companion to POV v4 draft-02 (canonical strategic) and Investor Deck v4 (14-slide walk). Structure derived from best-of-format review of Sequoia YouTube memo + a16z healthcare Series A guidance + Visible.vc founder-authored memo template + general VC best-practice (lead with recommendation + reasons + risks). ~8K words per Series A norm. Draft-01 intentionally surfaces gaps and open items for partner-review transparency; not a smoothed-over final.

End of investment memo v4-draft-02.